Business Context and Reporting Period
Company: Cardinal Health, Inc. (formerly Cardinal Distribution, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended March 31, 1994.
Key Event: The financial statements have been retroactively adjusted to reflect the merger with Whitmire Distribution Corporation, effective February 7, 1994. The Company also changed its fiscal year-end from March 31 to June 30.
Key Financial Metrics
| Metric | 3 Months Ended Mar 31, 1994 | 9 Months Ended Mar 31, 1994 |
|---|---|---|
| Net Sales | $1,510,674,000 | $4,199,913,000 |
| Gross Margin | $98,371,000 (6.51%) | $259,458,000 (6.18%) |
| Operating Earnings | $960,000 | $53,636,000 |
| Net Earnings (Loss) | $(8,930,000) | $18,489,000 |
| Net Earnings Available to Common | $(9,096,000) | $17,284,000 |
| Diluted EPS | $(0.29) | $0.55 |
| Cash and Equivalents (End of Period) | $311,000 | $311,000 |
| Notes Payable (Banks) | $92,300,000 | $92,300,000 |
| Long-Term Obligations | $210,277,000 | $210,277,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% in the quarter and 24% over the nine-month period compared to the prior year, driven by 20% internal growth and acquisitions (Solomons Company and PRN Services).
- Margin Compression: Gross margin percentage declined to 6.51% (quarter) and 6.18% (nine months) from 6.83% and 6.46% respectively, due to competitive pricing, a shift to higher-volume customers, and reduced purchasing gains.
- Profitability Impact: The Company reported a net loss of $8.9 million for the quarter, compared to a net earnings of $9.7 million in the prior year quarter. This was primarily due to a $35.9 million nonrecurring charge for Whitmire merger costs.
- Cash Flow: Net cash used in operating activities was $198.5 million for the nine months ended March 31, 1994, compared to $50.1 million used in the prior year. This was driven by significant increases in merchandise inventories ($273.4 million) and trade receivables ($65.6 million).
- Debt Structure: Long-term obligations decreased from $274.9 million to $210.3 million, largely due to the conversion of $74.9 million in Subordinated Debentures to equity and repayment of Whitmire's revolving credit, partially offset by the issuance of $100 million in new Notes.
Guidance, Outlook, and Risks
- Merger Integration: The Company recorded a $28.2 million (net of tax) nonrecurring charge for estimated Whitmire merger and integration costs, including transaction fees, restructuring, and IT integration. Actual expenses may differ.
- Margin Outlook: Management expects the decline in gross margin rates to continue in the immediate future but not in the long term.
- Liquidity: The Company maintains $326 million in line-of-credit agreements, with $233.7 million available. Management believes resources are adequate for capital expenditures and debt service.
- Legal Proceedings: The Company and Whitmire are defendants in consolidated class-action lawsuits regarding alleged price-fixing in the wholesale drug market. The Company intends to contest these allegations vigorously.
- Future Acquisitions: An agreement was signed on April 27, 1994, to acquire Humiston-Keeling, Inc., expected to close by July 1994.
Investor Verification Checklist
- Verify the accuracy of the $28.2 million merger cost estimate and the potential for additional integration expenses.
- Monitor the trend of gross margin compression and the Company's ability to stabilize margins as integration completes.
- Assess the impact of the significant increase in working capital requirements (inventory and receivables) on future cash flow.
- Review the status of the "Brand Name Prescription Drug Litigation" and potential liability exposure.
- Confirm the closing date and financial impact of the pending Humiston-Keeling acquisition.